Leader Research | Hamilton, Canada
Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:
Treatment with any of the following medications or therapies within 1 week, prior to Day 1:
Primary purpose
Allocation
Interventional model
Masking
769 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal